Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has led to a concerning resurgence of mucormycosis. More than 47,000 cases of mucormycosis were reported in three months from India. We update our systematic review on COVID-19-associated mucormycosis (CAM) till June 21st, 2021, comparing cases reported from India and elsewhere. We included individual patient details of 275 cases of CAM, of which 233 were reported from India and 42 from the rest of the world. Diabetes mellitus was the most common underlying risk factor for CAM in India than in other countries. The fatality rate of cases reported from India (36.5%) was less than the globally reported cases (61.9%), probably due to the predominance of rhino-orbital mucormycosis. On a multivariate analysis, we found that pulmonary or disseminated mucormycosis cases and admission to the intensive care unit were associated with increased mortality, while combination medical therapy improved survival. The paucity of pulmonary and disseminated mucormycosis cases from India suggests that these cases were either not diagnosed or reported, further supported by a trend of search data from the Google search engine. In this review, we discuss the factors explaining the substantial rise in cases of CAM. We also propose a hypothetical model describing the epidemiologic triad of CAM.

• Authors: Valliappan Muthu, Shivaprakash M Rudramurthy, Arunaloke Chakrabarti, Ritesh Agarwal
• Journal: Mycopathologia (Mycopathologia) Vol. 186 Issue 6 Pg. 739-754 (Dec 2021) ISSN: 1573-0832 [Electronic] Netherlands
• PMID: 34414555 (Publication Type: Journal Article, Review, Systematic Review)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Topics

• COVID-19
• Diabetes Mellitus
• Humans
• India (epidemiology)
• Mucormycosis (diagnosis, drug therapy, epidemiology)
• Risk Factors
• SARS-CoV-2